Targeting the NF-E2-related factor 2 pathway: A novel strategy for glioblastoma (Review)
- Authors:
- Jianhong Zhu
- Handong Wang
- Youwu Fan
- Yixing Lin
- Li Zhang
- Xiangjun Ji
- Mengliang Zhou
-
Affiliations: Department of Neurosurgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China - Published online on: June 12, 2014 https://doi.org/10.3892/or.2014.3259
- Pages: 443-450
This article is mentioned in:
Abstract
 |
 |
 |
|
Binello E and Germano IM: Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci. 102:1958–1966. 2011. View Article : Google Scholar | |
|
Van Meir EG, Hadjipanayis CG, Norden AD, et al: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010.PubMed/NCBI | |
|
Kensler TW, Wakabayashi N and Biswal S: Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89–116. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Wang F, Zhang L, et al: Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell Signal. 23:1625–1632. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bryan HK, Olayanju A, Goldring CE and Park BK: The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 85:705–717. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Livingston DM and Silver DP: Cancer: crossing over to drug resistance. Nature. 451:1066–1067. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Q, Li W, Wan Y, et al: Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology. 55:1820–1829. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Newlands ES, Stevens MF, Wedge SR, et al: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585–2597. 2000.PubMed/NCBI | |
|
Cong ZX, Wang HD, Zhou Y, et al: Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells. J Neurooncol. 116:41–48. 2014. View Article : Google Scholar | |
|
Hu XF, Yao J, Gao SG, et al: Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev. 14:5231–5235. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang T, Chen N, Zhao F, et al: High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 70:5486–5496. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XJ, Sun Z, Villeneuve NF, et al: Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 29:1235–1243. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CC, Chu CB, Liu KJ, et al: Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol. 86:872–887. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao AM, Ke ZP, Shi F, et al: Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact. 206:100–108. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao AM, Ke ZP, Wang JN, et al: Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 34:1806–1814. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim WD, Kim YW, Cho IJ, et al: E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J Cell Sci. 125:1284–1295. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lau A, Villeneuve NF, Sun Z, et al: Dual roles of Nrf2 in cancer. Pharmacol Res. 58:262–270. 2008. View Article : Google Scholar | |
|
Singh A, Wu H, Zhang P, et al: Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther. 9:2365–2376. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JH, Bogner PN, Ramnath N, et al: Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 13:3875–3882. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Alexander BM, Ligon KL and Wen PY: Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 13:569–581. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Caruso C, Carcaterra M and Donato V: Role of radiotherapy for high grade gliomas management. J Neurosurg Sci. 57:163–169. 2013.PubMed/NCBI | |
|
Frosina G: DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res. 7:989–999. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Singh A, Bodas M, Wakabayashi N, et al: Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal. 13:1627–1637. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma PK and Varshney R: 2-Deoxy-D-glucose and 6-aminonicotinamide-mediated Nrf2 down regulation leads to radiosensitization of malignant cells via abrogation of GSH-mediated defense. Free Radic Res. 46:1446–1457. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Singh A, Yegnasubramanian S, et al: Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 9:336–346. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Na HK and Surh YJ: Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med. 67:353–365. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
DeNicola GM, Karreth FA, Humpton TJ, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Taguchi K, Motohashi H and Yamamoto M: Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 16:123–140. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Brigelius-Flohé R, Müller M, Lippmann D and Kipp AP: The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int J Cell Biol. 2012:4861472012.PubMed/NCBI | |
|
Lu SC: Regulation of glutathione synthesis. Mol Aspects Med. 30:42–59. 2009. View Article : Google Scholar | |
|
Balan M and Pal S: A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 289:3126–3137. 2014. View Article : Google Scholar | |
|
Yamadori T, Ishii Y, Homma S, et al: Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene. 31:4768–4777. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zou W, Chen C, Zhong Y, et al: PI3K/Akt pathway mediates Nrf2/ARE activation in human L02 hepatocytes exposed to low-concentration HBCDs. Environ Sci Technol. 47:12434–12440. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kong B, Qia C, Erkan M, et al: Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Front Physiol. 4:2462013. View Article : Google Scholar : PubMed/NCBI | |
|
Ji XJ, Chen SH, Zhu L, et al: Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model. Oncol Rep. 30:157–164. 2013.PubMed/NCBI | |
|
Crosas-Molist E, Bertran E, Sancho P, et al: The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression. Free Radic Biol Med. 69:338–347. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Li Y, Lv S and Tian Y: Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB. J Int Med Res. 41:1577–1585. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Singh A, Happel C, Manna SK, et al: Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 123:2921–2934. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Petrelli A, Perra A, Cora D, et al: MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology. 59:228–241. 2014. View Article : Google Scholar | |
|
Rachakonda G, Sekhar KR, Jowhar D, et al: Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene. 29:3703–3714. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pan H, Wang H, Zhu L, et al: The role of Nrf2 in migration and invasion of human glioma cell U251. World Neurosurg. 80:363–370. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Deryugina EI, Bourdon MA, Luo GX, et al: Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci. 110:2473–2482. 1997.PubMed/NCBI | |
|
Gan FF, Ling H, Ang X, et al: A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways. Toxicol Appl Pharmacol. 272:852–862. 2013.PubMed/NCBI | |
|
Zhang L, Wang N, Zhou S, et al: Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. J Exp Clin Cancer Res. 31:662012. View Article : Google Scholar : PubMed/NCBI | |
|
Thangasamy A, Rogge J, Krishnegowda NK, et al: Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion. J Biol Chem. 286:32115–32122. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bat-Chen W, Golan T, Peri I, et al: Allicin purified from fresh garlic cloves induces apoptosis in colon cancer cells via Nrf2. Nutr Cancer. 62:947–957. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Liu J and Chen SY: Over-expression of Nrf2 diminishes ethanol-induced oxidative stress and apoptosis in neural crest cells by inducing an antioxidant response. Reprod Toxicol. 42:102–109. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Arlt A, Sebens S, Krebs S, et al: Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 32:4825–4835. 2013. View Article : Google Scholar | |
|
Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Thomadaki H and Scorilas A: BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 43:1–67. 2006. View Article : Google Scholar | |
|
Heasman SA, Zaitseva L, Bowles KM, et al: Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget. 2:658–668. 2011.PubMed/NCBI | |
|
Niture SK and Jaiswal AK: INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death Differ. 18:439–451. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Attardi LD: The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat Res. 569:145–157. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rotblat B, Melino G and Knight RA: NRF2 and p53: Januses in cancer? Oncotarget. 3:1272–1283. 2012.PubMed/NCBI | |
|
Filomeni G, Piccirillo S, Rotilio G and Ciriolo MR: p38MAPK and ERK1/2 dictate cell death/survival response to different pro-oxidant stimuli via p53 and Nrf2 in neuroblastoma cells SH-SY5Y. Biochem Pharmacol. 83:1349–1357. 2012. | |
|
Lee YM, Auh QS, Lee DW, et al: Involvement of Nrf2-mediated upregulation of heme oxygenase-1 in mollugin-induced growth inhibition and apoptosis in human oral cancer cells. Biomed Res Int. 2013:2106042013.PubMed/NCBI | |
|
Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 51:1–28. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bollag W and Holdener EE: Retinoids in cancer prevention and therapy. Ann Oncol. 3:513–526. 1992.PubMed/NCBI | |
|
Clarke N, Germain P, Altucci L and Gronemeyer H: Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med. 6:1–23. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen LA, Sigman CC, Andreola F, et al: Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 21:1271–1279. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Leszczyniecka M, Roberts T, Dent P, et al: Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther. 90:105–156. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bobilev I, Novik V, Levi I, et al: The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells. Cancer Biol Ther. 11:317–329. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li K, Zhong C, Wang B, et al: Nrf2 expression participates in growth and differentiation of endometrial carcinoma cells in vitro and in vivo. J Mol Histol. 45:161–167. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Capaccione KM and Pine SR: The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 34:1420–1430. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wakabayashi N, Skoko JJ, Chartoumpekis DV, et al: Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by Notch signaling. Mol Cell Biol. 34:653–663. 2014.PubMed/NCBI | |
|
Kanzaki H, Shinohara F, Kajiya M and Kodama T: The Keap1/Nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling. J Biol Chem. 288:23009–23020. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jayakumar S, Kunwar A, Sandur SK, et al: Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim Biophys Acta. 1840:485–494. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XJ, Hayes JD, Henderson CJ and Wolf CR: Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA. 104:19589–19594. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tan KP, Kosuge K, Yang M and Ito S: NRF2 as a determinant of cellular resistance in retinoic acid cytotoxicity. Free Radic Biol Med. 45:1663–1673. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Wang HD, Zhu L, et al: Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Oncol Rep. 29:394–400. 2013.PubMed/NCBI | |
|
Fan W, Tang Z, Chen D, et al: Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy. 6:614–621. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon J, Han E, Bui CB, et al: Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1-Nrf2-Nqo1 cascade. EMBO Rep. 13:150–156. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Inami Y, Waguri S, Sakamoto A, et al: Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 193:275–284. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Digaleh H, Kiaei M and Khodagholi F: Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagy. Cell Mol Life Sci. 70:4681–4694. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI | |
|
Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Wang H, Sun Q, et al: Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer. 13:3802013. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai JJ, Dudakov JA, Takahashi K, et al: Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol. 15:309–316. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Zhang T, Dong Q, et al: Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis. 4:e5372013. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C, Teng L, Vu D, et al: The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release. J Biol Chem. 287:33720–33732. 2012. View Article : Google Scholar | |
|
Loseva P, Kostyuk S, Malinovskaya E, et al: Extracellular DNA oxidation stimulates activation of NRF2 and reduces the production of ROS in human mesenchymal stem cells. Expert Opin Biol Ther. 12(Suppl 1): S85–S97. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hoelzinger DB, Demuth T and Berens ME: Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst. 99:1583–1593. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer. 9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar | |
|
Folkins C, Man S, Xu P, et al: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67:3560–3564. 2007. View Article : Google Scholar | |
|
Zhou S, Ye W, Zhang M and Liang J: The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action. Crit Rev Eukaryot Gene Expr. 22:149–160. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ashino T, Yamamoto M, Yoshida T and Numazawa S: Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 33:760–768. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaur B, Khwaja FW, Severson EA, et al: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 7:134–153. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kweider N, Fragoulis A, Rosen C, et al: Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia. J Biol Chem. 286:42863–42872. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim TH, Hur EG, Kang SJ, et al: NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res. 71:2260–2275. 2011.PubMed/NCBI | |
|
Ji RC: Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett. 346:6–16. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Emara M and Allalunis-Turner J: Effect of hypoxia on angiogenesis related factors in glioblastoma cells. Oncol Rep. 31:1947–1953. 2014.PubMed/NCBI | |
|
Marampon F, Gravina GL, Zani BM, et al: Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. Int J Oncol. 44:2121–2131. 2014.PubMed/NCBI | |
|
Ji X, Wang H, Zhu J, et al: Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Int J Cancer. 135:574–584. 2014.PubMed/NCBI | |
|
Ji X, Wang H, Zhu J, et al: Correlation of Nrf2 and HIF-1α in glioblastoma and their relationships to clinicopathologic features and survival. Neurol Res. 35:1044–1050. 2013. | |
|
Shen H, Yang Y, Xia S, et al: Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus. Sep 13–2013.(Epub ahead of print). | |
|
Lee C, Park GH and Jang JH: Cellular antioxidant adaptive survival response to 6-hydroxydopamine-induced nitrosative cell death in C6 glioma cells. Toxicology. 283:118–128. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Meisen WH and Kaur B: How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma? Expert Rev Neurother. 13:341–343. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Huseini LM, Aw Yeang HX, Sethu S, et al: Nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) modulates dendritic cell immune function through regulation of p38 MAPK-cAMP-responsive element binding protein/activating transcription factor 1 signaling. J Biol Chem. 288:22281–22288. 2013. View Article : Google Scholar | |
|
Thimmulappa RK, Lee H, Rangasamy T, et al: Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 116:984–995. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rockwell CE, Zhang M, Fields PE and Klaassen CD: Th2 skewing by activation of Nrf2 in CD4+ T cells. J Immunol. 188:1630–1637. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Foresti R, Bains SK, Pitchumony TS, et al: Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res. 76:132–148. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Limonciel A and Jennings P: A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity. Toxins. 6:371–379. 2014. View Article : Google Scholar : PubMed/NCBI |
